# China NMPA Drug Inspection - Ningxia Mingde Traditional Chinese Medicine Pieces Co., Ltd.

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/ningxia-mingde-traditional-chinese-medicine-pieces-co-ltd/bbda07f2-a0d8-4490-90f1-2be747eee18c/
Source feed: China

> China NMPA drug inspection for Ningxia Mingde Traditional Chinese Medicine Pieces Co., Ltd. published July 09, 2020. Drug: . On July 9, 2020, the Gansu Provincial Drug Administration, operating under the National Medical Products Administration 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Drug Quality Announcement from Gansu Provincial Drug Administration
- Company Name: Ningxia Mingde Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2020-07-09
- Inspection Finding: Ten batches of drugs failed to meet regulations and quality standards.
- Action Taken: The relevant market supervision and management departments have taken necessary control measures such as sealing and seizing, and have filed or are in the process of filing cases against the units involved in the products in accordance with relevant laws and regulations. The results of the handling will be made public within three months. Market supervision and management bureaus of all cities and prefectures should strengthen supervision, urge them to find out the cause of the problem, formulate and implement rectification measures, and effectively eliminate potential risks.
- Summary: On July 9, 2020, the Gansu Provincial Drug Administration, operating under the National Medical Products Administration (NMPA), released a drug quality announcement detailing inspection results from the Lanzhou Municipal Food and Drug Inspection Institute and other testing bodies. The inspection identified 10 batches of substandard drugs across seven different pharmaceutical companies, including Ningxia Mingde Traditional Chinese Medicine Pieces Co., Ltd. The primary violations centered on the failure of these medicinal batches to meet mandatory quality and safety standards during sample testing. Under the existing national regulatory framework for drug supervision, the relevant market management departments have initiated immediate enforcement actions. These include the sealing and seizure of all identified non-compliant products to prevent further distribution. Furthermore, authorities have launched legal investigations into the responsible companies, with a requirement that final results be disclosed to the public within three months. Required actions for the involved entities include conducting detailed investigations into the root causes of the quality failures and implementing robust rectification measures to eliminate future risks. Local market supervision bureaus are tasked with monitoring these companies closely to ensure strict compliance with drug safety protocols and to safeguard public health within the pharmaceutical supply chain.

Company: https://www.globalkeysolutions.net/companies/ningxia-mingde-traditional-chinese-medicine-pieces-co-ltd/c477649c-c7b3-415e-85dd-052726467a93/